Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC 3 (Solve Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Solve Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADC 3 is an antibody-drug conjugate (ADC) currently under development by Solve Therapeutics for the treatment of solid tumors. The candidate is engineered using Solve's proprietary CloakLink™ hydrophilic linker technology, which is designed to optimize the performance and therapeutic index of ADCs. The molecule consists of a highly selective targeting antibody, a CloakLink™ linker, and a potent cytotoxic payload. This targeting antibody is specifically engineered to bind to a membrane receptor protein that is selectively expressed on solid-tumor malignancies. As of early 2024, ADC 3 is in the IND-enabling phase of development, and the specific molecular target and payload identity remain undisclosed.
Beyond the preview
Go deeper on ADC 3 (Solve Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC 3 (Solve Therapeutics).